Navigation Links
Alzheimer's Treatment Trials May Have Special Challenges
Date:7/28/2008

Studies may need larger pools of participants to accurately assess if drugs are effective

MONDAY, July 28 (HealthDay News) -- It may be harder to prove the effectiveness of new Alzheimer's disease therapies, because researchers have been having a hard time finding measurable decline in memory and thinking processes in the placebo groups the drugs are being tested against, according to two new reports.

Several discoveries may explain this, according to the reports, which are expected to be presented Monday in Chicago at the Alzheimer's Association's International Conference on Alzheimer's Disease.

In the first study, researchers looked at 87 randomized, double-blind, placebo-controlled Alzheimer clinical trials conducted between 1991 and 2005. Their analysis help set conditions that may be optimal in these types of trials.

"Based on our analysis, the most reliable approach to maximize the likelihood for demonstrating efficacy is to have a placebo group size greater than 200 and to use (cognitive testing methods) at least four times and in English," researcher Dr. Lon S. Schneider, professor of psychiatry and neurology at the University of Southern California Keck School of Medicine, said in a news release issued from the conference.

The second study, which looked at trials of the drug donepezil during the 1990s, showed that the length of the placebo study may be of increasing importance. Placebo groups experienced slower declines in cognitive functions in trials done later in the decade, but this was mitigated when the trial period was longer.

"Our results indicate that patients with Alzheimer's entering the later clinical trials appear to be experiencing a slower rate of decline in memory and thinking processes," researcher Roy Jones, director of The Research Institute for the Care of Older People, in Bath, England, said in the same news release. "These observations are potentially important for the future design of clinical trials in people with Alzheimer's. For example, it may be necessary to conduct longer duration research studies -- more than 24 weeks -- to ensure any effects of treatment can be fully evaluated."

More information

The Alzheimer's Association has more about Alzheimer's disease.



-- Kevin McKeever



SOURCE: Alzheimer's Association, news release, July 28, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Alzheimers Research Target May Be a Dead End
2. Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting
3. Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi
4. Researchers disprove long-standing belief about HIV treatment
5. Neurotherapeutics presents special issue on new treatments for Alzheimers disease
6. Clinical Trial Concluded For New Wrinkle Treatment
7. Has cancer spread? Research identifies best way to find answers so treatment can begin
8. Minimally Invasive Treatment Improves Male Fertility
9. Minimally invasive treatment improves male fertility
10. Clinical Trial for the Treatment of Inflammatory Bowel Disease Begins at Tel Aviv Sourasky Medical Center
11. Promising results in deep brain stimulation for patients with treatment-resistant depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... typically been previously exposed to more adverse experiences than children in the general ... trauma such as abuse, neglect or other family challenges. While no fault of ...
(Date:4/28/2017)... Harbor, Md. (PRWEB) , ... April 28, 2017 ... ... Care Association of America (UCAOA) and College of Urgent Care Medicine will host ... 2017 workshops, sessions and speakers will help those in the industry adapt to ...
(Date:4/28/2017)... ... April 28, 2017 , ... People are starting to accept that hearing ... aid doesn’t have the stigma it had when great-grandpa wore his hearing aids years ... in a NALA North American Speaker Series (NASS) segment. “He probably wore ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... which name the Creator responds to and which He does not. Yisrayl says with ... which one is the true name, but he says with a little Scripture, backed with ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer USA is pleased to ... 20+ years of experience within the beauty industry, ranging from marketing, retail support, ... high-end cosmetic brands, retail brands and outlets in Canada and New York. As ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, Inc. ... on providing the Urology, Uro/Gyn and Gynecology markets ... Ash Keswani has joined the Company as Senior ... newly created position, Mr. Keswani will report directly ... "Our organization is delighted that Ash ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ... their offering. ... for drug delivery technologies will rise from USD 20 Billion in ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology: